Bioinvent International AB
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 111
- Market Cap
- -
- Website
- http://www.bioinvent.com
Clinical Trials
27
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
- Conditions
- Melanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K MutatedMelanoma RecurrentMelanoma Stage III or IVMelanomaMelanoma Negative for bRAFMelanoma Negative for nRASMelanomasUveal Melanoma, Metastatic
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 35
- Registration Number
- NCT06784648
- Locations
- 🇩🇪
Charité - Universitatsmedizin Berlin, Berlin, Germany
🇩🇪University Hospital Essen, Essen, Germany
🇩🇪University Hospital Heidelberg, Heidelberg, Germany
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
- Conditions
- Solid TumorsNon Small Cell Lung CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 104
- Registration Number
- NCT06205706
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇪Charité Universitätsmedizin Berlin, Berlin, Germany
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- Conditions
- HER2-positive Gastric CancerMetastatic Gastroesophageal Junction AdenocarcinomaHER2-positive Metastatic Breast CancerHER2-positive Breast CancerMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 18
- Registration Number
- NCT05555251
- Locations
- 🇩🇪
Evang. Kliniken Essen-Mitte, Essen, Germany
🇩🇪Krankenhaus Nordwest, Frankfurt, Germany
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- Conditions
- Advanced MalignanciesOvarian CancerT-cell LymphomaMelanoma
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 176
- Registration Number
- NCT04752826
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇩🇰Rigshospitalet, Copenhagen, Denmark
A Study of BI-1206 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (KEYNOTE-A04)
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 197
- Registration Number
- NCT04219254
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸HealthPartners Institute - Regions Cancer Care Center,, Saint Paul, Minnesota, United States
🇺🇸Oklahoma University , Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- Prev
- 1
- 2
- 3
- Next
News
Transgene and BioInvent to Present Updated BT-001 Oncolytic Virus Data at ESMO 2025
Transgene and BioInvent will present updated Phase I data on BT-001, an armed oncolytic virus expressing anti-CTLA-4 antibody, at the ESMO Annual Meeting in Berlin from October 17-21, 2025.
BioInvent's BI-1206 Shows Promising Phase 1 Results in Combination with Pembrolizumab for Solid Tumors
BioInvent's Phase 1 study of BI-1206 combined with pembrolizumab demonstrated encouraging clinical activity in heavily pre-treated solid tumor patients, with one complete response and one partial response among 36 evaluable patients.
BioInvent Advances BI-1910 Anti-TNFR2 Antibody with Population Modeling Data at PAGE 2025
BioInvent successfully developed a population model to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad dose range, supporting optimal dose selection for upcoming Phase 2a studies.
BioInvent Reports Promising Results from Triple Combination Therapy for Non-Hodgkin's Lymphoma
BioInvent's Phase 2a study of BI-1206 in combination with rituximab and Calquence® shows a 63% objective response rate in the first eight non-Hodgkin's lymphoma patients evaluated.
FDA Grants Orphan Drug Designation to BioInvent's BI-1808 for T-cell Lymphoma Treatment
BioInvent's first-in-class anti-TNFR2 antibody BI-1808 receives FDA Orphan Drug Designation for treating T-cell lymphoma, providing development incentives and seven years of market exclusivity.
BioInvent Reports Promising Early Results from Triple Combination Therapy for Non-Hodgkin's Lymphoma
Initial data from BioInvent's Phase 1/2a study shows promising efficacy with BI-1206 combined with rituximab and Calquence in non-Hodgkin's lymphoma, with one complete response and one partial response in the first two patients.